Last Price$0.71Cboe Closing Price as of 3:58PM ET 8/10/22
Cboe Real-Time Quotes
Today's Change+0.004(0.50%)
Bid (Size)$0.67 (100)
Ask (Size)$0.71 (100)
Day Low / High$0.69 - 0.71
Volume978.9 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/10/2022


Sesen Bio Inc ( NASDAQ )

Price: $0.71
Change: +0.004 (0.50%)
Volume: 978.9 K
3:58PM ET 8/10/2022

Homology Medicines Inc ( NASDAQ )

Price: $2.88
Change: +0.42 (17.35%)
Volume: 282.3 K
4:00PM ET 8/10/2022

Harvard Bioscience Inc ( NASDAQ )

Price: $3.33
Change: -0.03 (0.89%)
Volume: 78.5 K
3:59PM ET 8/10/2022

Paratek Pharmaceuticals Inc ( NASDAQ )

Price: $2.93
Change: +0.32 (12.26%)
Volume: 576.4 K
4:00PM ET 8/10/2022

Ardelyx Inc ( NASDAQ )

Price: $0.91
Change: +0.03 (3.32%)
Volume: 1.5 M
3:58PM ET 8/10/2022

Read more news Recent News

-- Earnings Flash (SESN) SESEN BIO Reports Q2 Loss $-0.16
8:01AM ET 8/08/2022 MT Newswires


Sesen Bio Pauses Clinical Trial of Non-Muscle Invasive Bladder Cancer Therapy in US
8:10AM ET 7/18/2022 MT Newswires

Sesen Bio (SESN) said Monday it has paused the clinical development of Vicineum, its therapeutic candidate for non-muscle invasive bladder cancer, in the...

Sesen Bio Nixes Reverse Stock Split Plan; Shares Rise
11:04AM ET 6/17/2022 MT Newswires

Sesen Bio (SESN) said Friday that it is no longer seeking a reverse stock split of its common shares to avoid a potential delisting. The late-stage...

-- Earnings Flash (SESN) SESEN BIO Posts Q1 EPS $0.00
8:10AM ET 5/09/2022 MT Newswires


View all Commentary and Analysis

Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
12:56PM ET 6/02/2022 Seeking Alpha

The State Of Biotech In 2022
4:04AM ET 1/03/2022 Seeking Alpha

Sesen Bio: Interesting Price Drop After CRL
3:10PM ET 11/24/2021 Seeking Alpha

Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
9:11PM ET 11/16/2021 Seeking Alpha

Company Profile

Business DescriptionSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. View company web site for more details
Address245 First Street
Cambridge, Massachusetts 02142
Number of Employees24
Recent SEC Filing08/08/202210-Q
President, Chief Executive Officer & DirectorThomas R. Cannell
Chief Financial Officer & TreasurerMonica Forbes
Finance DirectorStephanie Vigue
Head of ResearchJeannick Cizeau

Company Highlights

Price Open$0.71
Previous Close$0.71
52 Week Range$0.37 - 6.04
Market Capitalization$141.5 M
Shares Outstanding199.5 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/14/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings2.93
Earnings per Share-$0.02
Beta vs. S&P 500N/A
Net Profit Margin244.30%
Return on Equity39.16%

Analyst Ratings as of 07/09/2022

Consensus RecommendationConsensus Icon
Powered by Factset